Inhibitors of microtubule polyglutamylation in mitosis for use as a medicament
AssigneesFundació Centre De Regulació GenòMica, Institució Catalana De Recerca I Estudis AvançAts
InventorsIsabelle Vernos, Ivan Zadra
Life of this patent
Estimating the term…
Abstract
The present invention refers to inhibitors of microtubule polyglutamylation in mitosis for use as a medicament, preferably in the treatment of diseases benefiting from the inhibition of microtubule polyglutamylation in mitosis, most preferably in the treatment of cancer.
Claims25
In vitro method for screening, identifying and/or producing compounds for treating a disease which comprises:
- a) Assessing TTLL11 enzyme activity once the candidate compound has been incubated with TTLL11 enzyme, and b) wherein if an inhibition of TTLL11 activity is observed, it is indicative that the candidate compound may be effective for treating a disease.
A method of treating a disease with inhibitors of microtubule polyglutamylation in mitosis.
Pharmaceutical composition comprising an inhibitor of microtubule polyglutamylation in mitosis and, optionally, pharmaceutically acceptable carriers or excipients.
(canceled)
(canceled)
(canceled)
(canceled)
In vitro method for the diagnosis and/or prognosis of a disease benefiting from the inhibition of microtubule polyglutamylation in mitosis which comprises assessing the level of expression of TTLL11 in a biological sample obtained from the patient, wherein the identification of a reduced level of expression of TTLL11, as compared with a pre-established level of expression measured in healthy control patients, is as indication that the patient is suffering from a disease benefiting from the inhibition of microtubule polyglutamylation in mitosis.
In vitro use of TTLL11 for the diagnosis and/or prognosis of a disease benefiting from the inhibition of microtubule polyglutamylation in mitosis.
Dependencies are inferred from the claim text.